-$0.26 EPS Expected for Fate Therapeutics Inc (FATE) This Quarter

Analysts expect Fate Therapeutics Inc (NASDAQ:FATE) to announce earnings per share (EPS) of ($0.26) for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Fate Therapeutics’ earnings, with estimates ranging from ($0.29) to ($0.18). Fate Therapeutics posted earnings of ($0.23) per share in the same quarter last year, which would suggest a negative year over year growth rate of 13%. The business is scheduled to issue its next quarterly earnings report on Monday, August 13th.

According to Zacks, analysts expect that Fate Therapeutics will report full year earnings of ($1.05) per share for the current fiscal year, with EPS estimates ranging from ($1.16) to ($0.82). For the next financial year, analysts forecast that the business will post earnings of ($1.12) per share, with EPS estimates ranging from ($1.48) to ($0.79). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Fate Therapeutics.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.05). The company had revenue of $1.00 million during the quarter, compared to the consensus estimate of $1.82 million. Fate Therapeutics had a negative net margin of 1,143.99% and a negative return on equity of 77.27%. The company’s quarterly revenue was up .0% on a year-over-year basis.

A number of analysts have issued reports on FATE shares. HC Wainwright downgraded shares of Fate Therapeutics from a “buy” rating to a “neutral” rating and set a $12.00 price target on the stock. in a report on Tuesday, March 6th. Piper Jaffray Companies reissued a “top pick” rating and issued a $20.00 price objective on shares of Fate Therapeutics in a research note on Tuesday, March 6th. Wells Fargo & Co reissued an “outperform” rating and issued a $19.00 price objective (up from $10.00) on shares of Fate Therapeutics in a research note on Tuesday, March 6th. BMO Capital Markets lifted their price objective on shares of Fate Therapeutics from $7.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 6th. Finally, Wedbush reissued an “outperform” rating and issued a $19.00 price objective on shares of Fate Therapeutics in a research note on Thursday, March 29th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. Fate Therapeutics has a consensus rating of “Buy” and a consensus price target of $15.00.

Several large investors have recently modified their holdings of FATE. Redmile Group LLC grew its stake in shares of Fate Therapeutics by 285.1% in the 4th quarter. Redmile Group LLC now owns 5,465,486 shares of the biopharmaceutical company’s stock worth $33,394,000 after buying an additional 4,046,428 shares in the last quarter. BlackRock Inc. grew its stake in shares of Fate Therapeutics by 70.2% in the 1st quarter. BlackRock Inc. now owns 2,903,009 shares of the biopharmaceutical company’s stock worth $28,332,000 after buying an additional 1,197,716 shares in the last quarter. Artal Group S.A. purchased a new position in shares of Fate Therapeutics during the 1st quarter worth about $8,296,000. JPMorgan Chase & Co. boosted its stake in shares of Fate Therapeutics by 1,371.4% during the 1st quarter. JPMorgan Chase & Co. now owns 427,420 shares of the biopharmaceutical company’s stock worth $4,172,000 after purchasing an additional 398,372 shares during the period. Finally, Millennium Management LLC boosted its stake in shares of Fate Therapeutics by 873.6% during the 4th quarter. Millennium Management LLC now owns 338,799 shares of the biopharmaceutical company’s stock worth $2,070,000 after purchasing an additional 303,999 shares during the period. 74.56% of the stock is owned by institutional investors and hedge funds.

Fate Therapeutics traded up $0.25, reaching $12.02, on Friday, according to Marketbeat.com. The company had a trading volume of 143,388 shares, compared to its average volume of 933,784. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.20 and a current ratio of 7.20. The company has a market cap of $622.14 million, a P/E ratio of -11.78 and a beta of 1.75. Fate Therapeutics has a 12 month low of $2.52 and a 12 month high of $14.45.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors.

Get a free copy of the Zacks research report on Fate Therapeutics (FATE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply